Год в сердечно-сосудистой медицине 2020: интервенционная кардиология

Статья опубликована: European Heart Journal (2021) 00, 1-19. doi:10.1093/eurheartj/ehaa1096

1. Lombardi CM, Carubelli V, Iorio A, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. JAMA Cardiol. 2020;5:1274-80.

2. Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41:2070-9.

3. Peretto G, Sala S, Caforio ALP. Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement. Eur Heart J. 2020;41:2124-5.

4. Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41:3827-35.

5. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41:1821-9.

6. Fernandez Gasso L, Maneiro Melon NM, Sarnago Cebada F, et al. Multivessel spontaneous coronary artery dissection presenting in a patient with severe acute SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41:3100-101.

7. Meyer P, Degrauwe S, Van Delden C, et al. Typical takotsubo syndrome triggered by SARSCoV-2 infection. Eur Heart J. 2020;41:1860.

8. Rivero F, Antuňa P, Cuesta J, Alfonso F. Severe coronary spasm in a COVID-19 patient. Catheter Cardiovasc Interv. 2020; doi:10.1002/ccd.29056.

9. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with COVID19 — a case series. N Engl J Med. 2020;382:2478-80.

10. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:1815-26.

11. Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76:1168-76.

12. Said K, El-Baghdady Y, Abdel-Ghany M. Acute coronary syndromes in developing countries during the COVID-19 pandemic. Eur Heart J. 2020;41:2518-21.

13. Pessoa-Amorim G, Camm CF, Gajendragadkar P, et al. Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. Eur Heart J Qual Care Clin Outcomes. 2020;6:210-6.

14. Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol. 2020;76:1375-84.

15. Baldi E, Sechi GM, Mare C, et al.; Lombardia CARe researchers. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. Eur Heart J. 2020;41:3045-54.

16. Rodriguez-Leor O, Cid-Alvarez B, Ojeda S, et al. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. REC Interv Cardiol. 2020;2:82-9.

17. De Luca G, Verdoia M, Cercek M, et al. Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI. J Am Coll Cardiol. 2020;76:2321-30.

18. De Rosa S, Spaccarotella C, Basso C, et al.; Societá Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083-8.

19. Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396:381-9.

20. Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. Eur Heart J. 2020;41:1839-51.

21. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395-407.

22. Spertus JA, Jones PG, Maron DJ, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020;382:1408-19.

23. Bangalore S, Maron DJ, O’Brien SM, et al.; ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382:1608-18.

24. Bangalore S, Maron DJ, Stone GW, Hochman JS. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation. 2020;142:841-57.

25. Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77.

26. Konigstein M, Giannini F, Banai S. The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives. Eur Heart J. 2018;39:925-33.

27. Kunadian V, Chieffo A, Camici PG, et al. EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders Internati. Eur Heart J. 2020;41:3504-20.

28. Reynolds HR, Maehara A, Kwong Ry Sedlak T, et al. Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of MINOCA in women. Circulation. 2020; doi:10.1161/CIRCULATIONAHA.120.052008.

29. Collet JP, Thiele H, Barbato E, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; doi:10.1093/eurheartj/ehaa575.

30. Brugaletta S. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction: 10-year follow-up of the multicenter randomized controlled EXAMINATION trial. Cardiovascular Therapeutics annual scientific symposium 2020. 15 October 2020.

31. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. Eur Heart J. 2019;40:283-91.

32. Kaura A, Sterne JAC, Trickey A, et al. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. Lancet. 2020;396:623-34.

33. Atti V, Gwon Y, Narayanan MA, et al. Multivessel versus culprit-only revascularization in STEMI and multivessel coronary artery disease: meta-analysis of randomized trials. JACC Cardiovasc Interv. 2020;13:1571-82.

34. Kim MC, Hyun JY, Ahn Y, et al. Optimal revascularization strategy in non-ST-segmentelevation myocardial infarction with multivessel coronary artery disease: culprit-only versus one-stage versus multistage revascularization. J Am Heart Assoc. 2020;9:e016575.

35. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol. 2020;5:1-8.

36. Bougouin W, Dumas F, Lamhaut L, et al.; the Sudden Death Expertise Center investigators. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. Eur Heart J. 2020;41:1961-71.

37. Kuno T, Takagi H, Ando T, et al. Safety and efficacy of mechanical circulatory support with Impella or intra-aortic balloon pump for high-risk percutaneous coronary intervention and/or cardiogenic shock: Insights from a network meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2020; doi:10.1002/ccd.29236.

38. Siannaccone M, Albani S, Giannini F, et al. Short-term outcomes of Impella in cardiogenic shock: a review and meta-analysis of observational studies. Int J Cardiol. 2020; doi:10.1016/j.ijcard.2020.09.044.

39. Lemor A, Hosseini Dehkordi SH, Basir MB, et al. Impella versus extracorporeal membrane oxygenation for acute myocardial infarction cardiogenic shock. Cardiovasc Revasc Med. 2020;21:1465-71.

40. Schrage B, Becher PM, Bernhardt A, et al. Left ventricular unloading is associated with lower mortality in cardiogenic shock patients treated with veno-arterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation. 2020;142:2095-106.

41. Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325-34.

42. Park D-W, Ahn J-M, Park H, et al.; On behalf of the PRECOMBAT Investigators. Tenyear outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the PRECOMBAT trial. Circulation. 2020;141:1437-46.

43. Stone GW, Kappetein AP, Sabik JF, et al.; EXCEL Trial Investigators. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019;381:1820-30.

44. Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, noninferiority NOBLE trial. Lancet. 2020;395:191-9.

45. D’Ascenzo F, De Filippo O, Elia E, et al. Percutaneous vs. surgical revascularization for patients with unprotected left main stenosis: a metaanalysis of 5-year follow-up randomized controlled trials. Eur Heart J Qual Care Clin Outcomes. 2020; doi:10.1093/ehjqcco/qcaa041.

46. Gallo M, Blitzer D, Laforgia PL, et al. Percutaneous coronary intervention versus coronary artery bypass graft for left main coronary artery disease: a meta-analysis. J Thorac Cardiovasc Surg. 2020; doi:10.1016/j.jtcvs.2020.04.010.

47. Ahmad Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41:3228-35.

48. Gregson J, Stone GW, Ben-Yehuda O, et al. Implications of alternative definitions of peri-procedural myocardial infarction after coronary revascularization. J Am Coll Cardiol. 2020;76:1609-21.

49. Giustino G, Serruys PW, Sabik JF, et al. Mortality after repeat revascularization following PCI or CABG for left main disease: the EXCEL trial. JACC Cardiovasc Interv. 2020;13:375-87.

50. Thuijs DJFM, Milojevic M, Stone GW, et al. Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. Eur J Heart Fail. 2020;22:871-9.

51. Wiebe J, Kuna C, Ibrahim T, et al. Long-term prognostic impact of restenosis of the unprotected left main coronary artery requiring repeat revascularization. JACC Cardiovasc Interv. 2020;13:2266-74.

52. Park S, Ahn J-M, Kim TO, et al. Revascularization in patients with left main coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2020;76:1395-406.

53. Tam DY, Dharma C, Rocha R, et al. Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease. J Am Coll Cardiol. 2020;76:1153-64.

54. Zhang JJ, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J. 2020;41:2523-36.

55. Gioia G, Di Sonck J, Ferenc M, et al. Clinical outcomes following coronary bifurcation PCI techniques: a systematic review and network meta-analysis comprising 5,711 patients. JACC Cardiovasc Interv. 2020;13:1432-44.

56. Gaido L, D’Ascenzo F, Imori Y, et al. Impact of kissing balloon in patients treated with ultrathin stents for left main lesions and bifurcations: an analysis from the RAINCARDIOGROUP VII study. Circ Cardiovasc Interv. 2020;13:e008325.

57. Kini AS, Dangas GD, Baber U, et al. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020;16:218-24.

58. Silverio A, Buccheri S, Venetsanos D, et al. Percutaneous treatment and outcomes of small coronary vessels: a SCAAR report. JACC Cardiovasc Interv. 2020;13:793-804.

59. Dan K, Garcia-Garcia HM, Kolm P, et al. Comparison of ultrathin, bioresorbable-polymer sirolimus-eluting stents and thin, durable-polymer everolimus-eluting stents in calcified or small vessel lesions. Circ Cardiovasc Interv. 2020;13:e009189.

60. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxelcoated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. 2020;41:3715-28.

61. Giacoppo D, Alfonso F, Xu B, et al. Drug-coated balloon angioplasty versus drugeluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol. 2020;75:2664-78.

62. Schumacher SP, Kockx M, Stuijfzand WJ, et al. Ischaemic burden and changes in absolute myocardial perfusion after chronic total occlusion percutaneous coronary intervention. EuroIntervention. 2020;16:e462-e471.

63. Xenogiannis I, Gkargkoulas F, Karmpaliotis D, et al. Retrograde chronic total occlusion percutaneous coronary intervention via saphenous vein graft. JACC Cardiovasc Interv. 2020;13:517-26.

64. Kalogeropoulos AS, Alsanjari O, Keeble TR, et al. CASTLE score versus J-CTO score for the prediction of technical success in chronic total occlusion percutaneous revascularisation. EuroIntervention. 2020;15:e1615-e1623.

65. Nagamatsu W, Tsuchikane E, Oikawa Y, et al. Successful guidewire crossing via collateral channel at retrograde percutaneous coronary intervention for chronic total occlusion: the J-Channel score. EuroIntervention. 2020;15:e1624-e1632.

66. Shoaib A, Rashid M, Kontopantelis E, et al. Clinical characteristics and outcomes from percutaneous coronary intervention of last remaining coronary artery: an analysis from the British Cardiovascular Intervention Society Database. Circ Cardiovasc Interv. 2020;13:e009049.

67. Kufner S, Ernst M, Cassese S, et al.; ISAR-TEST-5 Investigators. 10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents. J Am Coll Cardiol. 2020;76:146-58.

68. Jensen LO, Maeng M, Raungaard B, et al.; Sort Out IX Study Group. Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX trial. Circulation. 2020;141:2052-63.

69. Kim HS, Kang J, Hwang D, et al.; HOST-REDUCEPOLYTECH-ACS Randomized Clinical Trial Investigators. Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCEPOLYTECH-ACS trial. Circulation. 2020; doi:10.1161/CIRCULATIONAHA.120.051700.

70. DES with synchronized antiproliferative drug delivery to target smooth muscle cell proliferation after DES implantation in coronary artery disease. Primary results of the PIONEER III Trial. American Heart Association Scientific Sessions 2020. 15 November 2020.

71. Rocha-Singh KJ, Duval S, Jaff MR, et al.; On behalf of VIVA Physicians, Inc. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141:1859-69.

72. Scheller B, Vukadinovic D, Jeger R, et al. Survival after coronary revascularization with paclitaxel-coated balloons. J Am Coll Cardiol. 2020;75:1017-28.

73. Elgendy IY, Gad MM, Elgendy AY, et al. Clinical and angiographic outcomes with drugcoated balloons for de novo coronary lesions: a meta-analysis of randomized clinical trials. J Am Heart Assoc. 2020;9:e016224.

74. Cortese B, Di Palma G, Guimaraes MG, et al. Drug-coated balloon versus drug eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv. 2020;13:2840-9.

75. Kandzari DE, Koolen JJ, Doros G, et al.; BIOFLOW V Investigators. Ultrathin bioresorbablepolymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC Cardiovasc Interv. 2020;13:1343-53.

76. Takahashi K, Serruys PW, Kogame N, et al. Final 3-year outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: insights from the DESSOLVE III All-Comers Randomized Trial. Circ Cardiovasc Interv. 2020;13:e008737.

77. Hill JM, Kereiakes DJ, Shlofmitz RA, et al. Intravascular lithotripsy for treatment of severely calcified coronary artery disease: the Disrupt CAD III study. J Am Coll Cardiol. 2020;76:2635-46.

78. Tonino PAL, Pijls NHJ, Collet C, et al.; TIDES-ACS Study Group. Titanium-nitrideoxidecoated versus everolimus-eluting stents in acute coronary syndrome: the Randomized TIDES-ACS trial. JACC Cardiovasc Interv. 2020;13:1697-705.

79. Sabaté M, Alfonso F, Cequier A, et al. Magnesium-based resorbable scaffold versus permanentmetallicsirolimus-elutingstentinpatientswith ST-segmentelevationmyocardial infarction: the MAGSTEMI Randomized Clinical Trial. Circulation. 2019;140:1904-16.

80. Gomez-Lara J, Ortega-Paz L, Brugaletta S, et al., Collaborators. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-Segment Elevation Myocardial Infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention. 2020;16:e913-e921.

81. Ueki Y, Räber L, Otsuka T, et al. Mechanism of drug eluting absorbable metal scaffold restenosis: a serial optical coherence tomography study. Circ Cardiovasc Interv. 2020;13:e008657.

82. Hong S-J, Mintz GS, Ahn C-M, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow up of the IVUS-XPL Randomized trial. JACC Cardiovasc Interv. 2020;13:62-71.

83. Gao X-F, Ge Z, Kong X-Q, et al.; ULTIMATE Investigators. Three-year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drugeluting stent implantation. J Am Coll Cardiol Cardiovasc Interv. 2020; doi:10.1016/j.jcin.2020.10.001.

84. Hong SJ, Kim D, Kim BK, et al. Acute and one-year clinical outcomes of pre-stenting intravascular ultrasound: a patient-level meta-analysis of randomised clinical trials. EuroIntervention. 2020; doi:10.4244/EIJ-D-20-00276.

85. Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single-center trial. JACC Cardiovasc Interv. 2020;13:49-58.

86. Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41:383-91.

87. Kedhi E. Combined optical coherence tomography and fractional flow reserve assessment to better predict adverse event outcomes in DM patients. Presented at: TCT 2020. 14 October 2020.

88. Pinilla-Echeverri N, Mehta SR, Wang J, et al. Nonculprit lesion plaque morphology in patients with ST-segment-elevation myocardial infarction: results from the COMPLETE Trial Optical Coherence Tomography Substudys. Circ Cardiovasc Interv. 2020;13:e008768.

89. Stone GW, Maehara A, Ali ZA, et al.; PROSPECT ABSORB Investigators. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J Am Coll Cardiol. 2020;76:2289-301.

90. Kuramitsu S, Matsuo H, Shinozaki T, et al. Two-year outcomes after deferral of revascularization based on fractional flow reserve: the J-CONFIRM Registry. Circ Cardiovasc Interv. 2020;13:e009049.

91. Parikh RV, Liu G, Plomondon ME, et al. Utilization and outcomes of measuring fractional flow reserve in patients with stable ischemic heart disease. J Am Coll Cardiol. 2020;75:409-19.

92. Warisawa T, Cook CM, Rajkumar C, et al. Safety of revascularization deferral of left main stenosis based on instantaneous wave free ratio evaluation. JACC Cardiovasc Interv. 2020;13:1655-64.

93. Jeremias A, Davies JE, Maehara A, et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary intervention: the DEFINE PCI study. JACC Cardiovasc Interv. 2019;12:1991-2001.

94. Patel M, Jeremias A, Davies J. One-year outcomes of patients with residual physiologic ischemia after percutaneous coronary intervention: the DEFINE PCI trial. Cardiovascular Therapeutics annual scientific symposium 2020. 15 October 2020.

95. Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41:3533-45.

96. Kim BK, Hong SJ, Cho YH, et al.; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO Randomized Clinical Trial. JAMA. 2020;323:2407-16.

97. Windecker S, Latib A, Kedhi E, et al.; ONYX ONE Investigators. Polymer-based or polymerfree stents in patients at high bleeding risk. N Engl J Med. 2020;382:1208-18.

98. Mehran R. The XIENCE Short DAPT Program: XIENCE 90/28 evaluating the safety of 3and 1-month DAPT in HBR patients. Transcatheter Cardiovascular Therapeutics annual scientific symposium 2020. 15 October 2020.

99. Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation 2020;142:150-60.

100. Kim HS, Kang J, Hwang D, et al.; HOST-REDUCE-POLYTECHACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCEPOLYTECH-ACS): an open-label, multicentre, noninferiority randomised trial. Lancet. 2020;396:1079-89.

101. Tarantini G, Mojoli M, Varbella F, et al.; DUBIUS Investigators, on behalf of the Italian Society of Interventional Cardiology (SICI-GISE). Timing of oral P2Y12 inhibitor administration in non-ST elevation acute coronary syndrome. J Am Coll Cardiol. 2020;76:2450-9.

102. Vlachojannis GJ, Wilschut JM, Vogel RF, et al. COMPARE CRUSH: a randomized trial of prehospital crushed vs uncrushed prasugrel in STEMI. Circulation. 2020;142:2316-28.

103. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST elevation acute coronary syndrome (POPular AGE): the randomised, open label, non-inferiority trial. Lancet. 2020;395:1374-81.

104. Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART Registry. Circulation. 2020;142:1700-8.

105. Hong MK. One-month dual antiplatelet therapy followed by aspirin monotherapy after drug-eluting stent implantation: randomized One-Month DAPT trial. American Heart Association Scientific Sessions 2020. 15 November 2020.

106. Bainey KR, Welsh RC, Connolly SJ, et al.; On behalf of the COMPASS Investigators. Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation. 2020;141:1141-51.

107. Silvain J, Lattuca B, Beygui F, et al.; ALPHEUS investigators. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;396:1737-44.

108. Barbato E, Noc M, Baumbach A, et al. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. Eur Heart J. 2020;41:2579-88.

109. Timmis A, Townsend N, Gale CP, et al.; European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12-85.